BioCentury
ARTICLE | Clinical News

Indacaterol/glycopyrronium bromide: Phase III data

November 23, 2015 8:00 AM UTC

Top-line data from the double-blind, international Phase III FLAME trial in 3,362 patients with moderate to very severe COPD showed that once-daily 110/50 ug Ultibro Breezhaler met the primary endpoint of non-inferiority to Seretide salmeterol/fluticasone propionate in reducing the rate of COPD exacerbations over 52 weeks. Ultibro Breezhaler was also superior to Seretide on the endpoint. ...